Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) Net Income towards Common Stockholders (2024 - 2025)

Historic Net Income towards Common Stockholders for Pyxis Oncology (PYXS) over the last 2 years, with Q3 2025 value amounting to -$22.0 million.

  • Pyxis Oncology's Net Income towards Common Stockholders fell 377.31% to -$22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.6 million, marking a year-over-year change of. This contributed to the annual value of -$77.3 million for FY2024, which is 465.69% down from last year.
  • Latest data reveals that Pyxis Oncology reported Net Income towards Common Stockholders of -$22.0 million as of Q3 2025, which was down 377.31% from -$18.4 million recorded in Q2 2025.
  • In the past 5 years, Pyxis Oncology's Net Income towards Common Stockholders ranged from a high of -$4.0 million in Q1 2024 and a low of -$35.6 million during Q4 2024